POAI stock icon

Predictive Oncology

0.8030 USD
+0.0472
6.25%
At close Dec 6, 4:00 PM EST
After hours
0.7703
-0.0327
4.07%
1 day
6.25%
5 days
1.59%
1 month
4.29%
3 months
-12.24%
6 months
-38.23%
Year to date
-77.25%
1 year
-75.59%
5 years
-98.67%
10 years
-99.66%
 

About: Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

Employees: 35

0
Funds holding %
of 6,790 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

4.01% less ownership

Funds ownership: 7.04% [Q2] → 3.03% (-4.01%) [Q3]

6% less funds holding

Funds holding: 18 [Q2] → 17 (-1) [Q3]

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

48% less capital invested

Capital invested by funds: $300K [Q2] → $157K (-$143K) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for POAI.

Financial journalist opinion

Neutral
GlobeNewsWire
3 weeks ago
Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update
Company initiates process to explore a broad range of strategic alternatives to maximize shareholder value Company initiates process to explore a broad range of strategic alternatives to maximize shareholder value
Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update
Neutral
GlobeNewsWire
3 months ago
Predictive Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
PITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, is scheduled to deliver a virtual presentation and host investor one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held September 9th through 11th in New York, NY.
Predictive Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Neutral
Seeking Alpha
3 months ago
Predictive Oncology Inc. (POAI) Q2 2024 Earnings Call Transcript
Predictive Oncology Inc. (NASDAQ:POAI ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Glenn Garmont – Investor Relations Raymond Vennare – Chairman and Chief Executive Officer Josh Blacher – Chief Financial Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Second Quarter 2024 Earnings Conference Call.
Predictive Oncology Inc. (POAI) Q2 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
3 months ago
Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update
Company to host investor call and webcast today, August 14th, at 8:30am EDT Company to host investor call and webcast today, August 14th, at 8:30am EDT
Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update
Neutral
GlobeNewsWire
4 months ago
Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024
PITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, 2024 before the markets open on Wednesday, August 14, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m.
Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024
Neutral
GlobeNewsWire
4 months ago
Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 958,117 shares of its common stock having a current exercise price of $14.00 originally issued in February 2021, June 2021 and May 2022, at a reduced exercise price of $1.32 per share. The issuance and/or resale of the shares of common stock issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form S-1 (File No. 333-267689), Form S-3 (File No. 254309) and Form S-3 (333-255582). The gross proceeds to Predictive Oncology from the exercise of the existing warrants are expected to be approximately $1.26 million, prior to deducting placement agent fees and transaction expenses payable by the Company.
Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds
Positive
InvestorPlace
4 months ago
Why Is Predictive Oncology (POAI) Stock Up 70% Today?
Shares of biotechnology specialist Predictive Oncology (NASDAQ: POAI ) — which leverages artificial intelligence (AI) and machine learning models for the discovery of novel biomarkers in cancer research protocols — soared on Thursday. Earlier, the company announced a major development in terms of the predictability models of ovarian cancer.
Why Is Predictive Oncology (POAI) Stock Up 70% Today?
Neutral
GlobeNewsWire
4 months ago
Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
Expands AI/ML driven offering to include novel oncology biomarker discovery to predict patient outcomes and drug response in oncology
Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
Neutral
GlobeNewsWire
5 months ago
Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)
Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development
Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)
Neutral
GlobeNewsWire
6 months ago
Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
Predictive Oncology's organ-specific in vitro models are designed to better mimic  the physiological environment of human tissue
Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
Charts implemented using Lightweight Charts™